Prostate cancer
"last update: 28 April 2024"
- Annexes
Table 1 : Risk stratification according to clinical /Pathologic features
NCCN Clinical Practice Guidelines in Oncology for prostate cancer , version 4.2023
Table 2 : Definitions of active surveillance and watchful waiting
|
Active surveillance |
Watchful waiting |
|
|
Treatment intent |
Curative |
Palliative |
|
Follow-up |
Pre-defined schedule |
Patient-specific |
|
Assessment/markers used |
DRE, PSA, MRI at recruitment, re-biopsy |
Not pre-defined, but dependent on development of symptoms of progression |
|
Life expectancy |
> 10 years |
< 10 years |
|
Aim |
Minimise treatment-related toxicity without compromising survival |
Minimise treatment-related toxicity |
|
Eligible patients |
Mostly low-risk patients |
Can apply to patients with all stages |
EAU Recommendations
Table 3 : AJCC TNM staging system for prostate cancer
Table 4 : : Definition of Histologic Grade Group (G)
Recently, the Gleason system has been compressed into so-called Grade Groups.
Table 5 : Doses and fractionation of EBRT , Brachytherapy and combined
NCCN Clinical Practice Guidelines in Oncology for prostate cancer , version 4.2023
